Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20681543rdf:typepubmed:Citationlld:pubmed
pubmed-article:20681543lifeskim:mentionsumls-concept:C0597032lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C0431085lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C0596290lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C0037638lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C0220807lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C1704241lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:20681543lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:20681543pubmed:issue16lld:pubmed
pubmed-article:20681543pubmed:dateCreated2010-8-19lld:pubmed
pubmed-article:20681543pubmed:abstractTextThe reactions of cyclopropylamine, cyclopentylamine, and cyclohexylamine with trans-[PtCl2(NCMe)2] afforded the bis-cationic complexes trans-[Pt(amine)2(Z-amidine)2]2+[Cl-]2, 1-3. The solution behavior and biological activity have been studied in different solvents (DMSO, water, polyethylene glycol (PEG 400), and polyethylene glycol dimethyl ether (PEG-DME 500)). The biological activity was strongly influenced by the cycloaliphatic amine ring size, with trans-[Pt(NH2CH(CH2)4CH2)2{N(H) horizontal lineC(CH3)N(H)CH(CH2)4CH2}2]2+[Cl-]2 (3) being the most active compound. Complex 3 overcame both cisplatin and MDR resistance, inducing cancer cell death through p53-mediated apoptosis. Alkaline single-cell gel electrophoresis experiments indicated direct DNA damage, reasonably attributable to DNA adducts of trans-[PtCl(amine)(Z-amidine)2][Cl] species, which can evolve to produce disruptive and nonrepairable lesions on DNA, thus leading to the drug-induced programmed cancer cell death. Preliminary in vivo antitumor studies on C57BL mice bearing Lewis lung carcinoma highlighted that complex 3 promoted a significant and dose-dependent tumor growth inhibition without adverse side effects.lld:pubmed
pubmed-article:20681543pubmed:languageenglld:pubmed
pubmed-article:20681543pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:citationSubsetIMlld:pubmed
pubmed-article:20681543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20681543pubmed:statusMEDLINElld:pubmed
pubmed-article:20681543pubmed:monthAuglld:pubmed
pubmed-article:20681543pubmed:issn1520-4804lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:SeragliaRober...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:MarzanoCristi...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:BertaniRobert...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:Del...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:VenzoAlfonsoAlld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:BenetolloFran...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:GandinValenti...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:ColavitoDavid...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:MichelinRino...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:Mazzega...lld:pubmed
pubmed-article:20681543pubmed:authorpubmed-author:SchiavonMaria...lld:pubmed
pubmed-article:20681543pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20681543pubmed:day26lld:pubmed
pubmed-article:20681543pubmed:volume53lld:pubmed
pubmed-article:20681543pubmed:ownerNLMlld:pubmed
pubmed-article:20681543pubmed:authorsCompleteYlld:pubmed
pubmed-article:20681543pubmed:pagination6210-27lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:meshHeadingpubmed-meshheading:20681543...lld:pubmed
pubmed-article:20681543pubmed:year2010lld:pubmed
pubmed-article:20681543pubmed:articleTitleA new class of antitumor trans-amine-amidine-Pt(II) cationic complexes: influence of chemical structure and solvent on in vitro and in vivo tumor cell proliferation.lld:pubmed
pubmed-article:20681543pubmed:affiliationDepartment of Pharmaceutical Sciences, Universy of Padova, Via F. Marzolo 5, I-35131 Padova, Italy.lld:pubmed
pubmed-article:20681543pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20681543pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed